RxDoctor Payments Data

Theresa Ezenwajiaku

Nurse Practitioner · Bowie, MDNPI 1053047977

Payments from drug & device makers

$3,754in general payments, 2019–2025

Across 181 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$497
  • Novo Nordisk$413
  • Amgen$293
  • AbbVie$289
  • Gilead$281
  • Lilly USA, LLC$259
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$3,73499%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,754 in reported general payments places this provider in the 90th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$38,445
Medicare patients
212
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban14$19,669
JardianceEmpagliflozin20$18,487
RybelsusSemaglutide13$17,655
Atorvastatin Calcium65$498
Albuterol Sulfate HfaAlbuterol Sulfate14$461
Metformin Hcl37$385
Omeprazole21$302
Tamsulosin Hcl19$283
Levothyroxine Sodium27$253
Amlodipine Besylate53$219
Cyclobenzaprine Hcl14$204
Pantoprazole Sodium12$149
Losartan Potassium26$132
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$124
Latanoprost11$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$114$19,66925 claims
Boehringer IngelheimJardiance$121$18,48720 claims
Novo NordiskRybelsus$413$17,65513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Bowie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →